Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a
- 1 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (7), 1063-1073
- https://doi.org/10.1158/1541-7786.MCR-19-0852
Abstract
Multiple myeloma remains incurable due to the persistence of a minor population of multiple myeloma cells that exhibit drug resistance, which leads to relapsed and/or refractory multiple myeloma. Elucidating the mechanism underlying drug resistance and developing an effective treatment are critical for clinical management of multiple myeloma. Here we showed that promoting expression of the gene for polycomb-like protein 3 (PHF19) induced multiple myeloma cell growth and multidrug resistance in vitro and in vivo. PHF19 was overexpressed in high-risk and drug-resistant primary cells from patients. High levels of PHF19 were correlated with inferior survival of patients with multiple myeloma, in the Total Therapy 2 cohort and in the Intergroup Francophone du Myeloma (IFM) cohort. Enhancing PHF19 expression levels increased Bcl-xL, Mcl-1, and HIF-1a expression in multiple myeloma cells. PHF19 also bound directly with EZH2 and promoted the phosphorylation of EZH2 through PDK1/AKT signaling. iniR-15a is a small noncoding RNA that targeted the 3'UTR of PHF19. We found that downregulation of miR-15a led to high levels of PHF19 in multiple myeloma cells. These findings revealed that PHF19 served a crucial role in multiple myeloma proliferation and drug resistance and suggested that the miR-15a/PHF19/EZH2 pathway made a pivotal contribution to multiple myeloma pathogenesis, offering a promising approach to multiple myeloma treatment.Other Versions
Funding Information
- Natural Science Foundation of China (81570181, 81400174, 81630007, 81920108006)
- Chinese Academy of Medical Sciences
- Innovation Fund for Medical Sciences (CAMS-2016-I2M-3-031, CAMS-2017-I2M-1-005, CAMS 2017-I2M-1-015)
- Tianjin Science and Technology Supporting Program (17JCYBJC27900)
- non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018RC320012)
This publication has 39 references indexed in Scilit:
- NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other CancersCancer Cell, 2013
- Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiationNature Structural & Molecular Biology, 2012
- Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activityNature Structural & Molecular Biology, 2012
- PHF19 and Akt control the switch between proliferative and invasive states in melanomaCell Cycle, 2012
- EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complexNature Communications, 2012
- Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cellsJournal of Hematology & Oncology, 2011
- Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expressionLeukemia & Lymphoma, 2011
- The molecular classification of multiple myelomaBlood, 2006
- Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3Science, 2005
- A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancersGene, 2004